Kyntra Bio financials
$6.79−1.59%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 |
|---|---|---|
| Revenue | -$1.5M | $3.7M |
| Gross profit | -$1.5M | -$368.0K |
| Gross margin | 100.1% | −9.8% |
| Operating income | -$17.6M | -$13.8M |
| Net income | $12.0M | -$15.2M |
| Net margin | −812.3% | −406.6% |
| Diluted EPS | $2.96 | $-3.76 |
| EBITDA | -$17.6M | -$13.8M |
| Operating cash flow | -$4.0M | -$13.9M |
| Free cash flow | -$4.0M | -$13.9M |
| Diluted shares | 4.0M | 4.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 |
|---|---|---|
| Cash & equivalents | $50.6M | $37.0M |
| Short-term investments | $40.7M | $50.2M |
| Total debt | $0.00 | $0.00 |
| Total assets | $101.1M | $109.6M |
| Total liabilities | $109.2M | $118.9M |
| Shareholders' equity | -$29.6M | -$30.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology